APRIL and BAFF/APRIL Blockade in IgA Nephropathy: Systematic Review and Meta-analysis

Six randomized controlled trials form the basis of this meta-analysis evaluating emerging therapies for IgA nephropathy. The dataset, shared by 妍 陈 on figshare, contains results from a systematic review covering literature up to March 22, 2026. It includes meta-analyses on proteinuria reduction, eGFR change, humoral immune biomarkers, and safety outcomes for therapies targeting the APRIL and BAFF/APRIL axis.

Use Cases

• Compare efficacy of selective APRIL blockade versus dual BAFF/APRIL blockade based on the prespecified subgroup analyses mentioned in the description
• Analyze the relationship between proteinuria reduction and changes in specific biomarkers like Gd-IgA1, IgA, IgG, and IgM
• Assess the safety profile of targeted immunotherapies by examining infection risk data from the included trials

Strengths

• Analysis is based on six double-blind, parallel-group randomized controlled trials, a rigorous study design
• The review includes data from five major databases (PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov) from inception to March 2026
• Results include specific statistical measures, such as a proteinuria reduction ratio of means of 0.55 with a 95% CI of 0.48 to 0.63

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The description notes mature phase 3 eGFR slope data were unavailable, indicating a data gap

Provenance

Source

Systematic review and meta-analysis of published randomized controlled trials.

Collection Method

Literature search across PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov, followed by random-effects meta-analyses.

Time Range

Literature from database inception to March 22, 2026.

Freshness

Last updated 2026-05-12 16:47:25; freshness should be verified